COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Cohance Lifesciences (formerly Suven Pharmaceuticals) has filed its Annual Secretarial Compliance Report for FY ended March 2026. The secretarial auditor Makarand M. Joshi & Co. examined compliance with SEBI regulations and found the company largely compliant. One deviation was noted: the company delayed filing "Integrated Filing – Financial" in XBRL format with BSE – submitting on September 9, 2025 instead of the same day as the NSE filing (for Q1 FY26 results approved on August 13, 2025). Additionally, one related party transaction was not pre-approved by the Audit Committee but was subsequently ratified with an enhanced limit. No SEBI or Stock Exchange actions were taken against the company, its promoters, directors, or subsidiaries during the review period.
This is a routine compliance filing with minimal shareholder impact. The single XBRL filing delay and related party transaction ratification are minor procedural issues that do not affect the company's financial health or operations. The overall clean compliance report is neutral-to-positive for investors.